26% of primary cSCC tumors from immunocompetent patients exhibit PD-L1+ tumor cells, 60% of cSCC harbor PD-L1+ infiltrating immune cells, and 81% have PD-1+/CD8+ T cells [184]. Here, CD8A is linked to neoplasm.